Nachrichten zur Ardelyx Aktie

Ardelyx Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

Conference call scheduled for 8:00 a.m. Eastern Time Conference call scheduled for 8:00 a.m. Eastern Time...…

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma Acceptance of NDA Submission triggers…

Insiderhandel: Chief Medical Officer verkauft Aktien von Ardelyx im Wert von 83.633$

Williams, Laura A. - Vorstand - Tag der Transaktion: 2023-06-27...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission…

Insiderhandel: Vorstand verkauft Aktien von Ardelyx im Wert von 121.042$

Blanks, Robert - Vorstand - Tag der Transaktion: 2023-06-23...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission…

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

User Fee Goal Date: October 17, 2023 User Fee Goal Date: October 17, 2023...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...…

Ardelyx resubmits NDA for Xphozah to US FDA

A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD)…

Ardelyx resubmits NDA to FDA for tenapanor for chronic kidney disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of…

Insiderhandel: Chief Development Officer verkauft Aktien von Ardelyx im Wert von 13.888$

Rosenbaum, David P. - Vorstand - Tag der Transaktion: 2023-03-29...…

Ardelyx (ARDX) Gains As Market Dips: What You Should Know

In the latest trading session, Ardelyx (ARDX) closed at $4.05, marking a +0.5% move from the previous day....…

Ardelyx Shares Rally on 4Q Update, Bullish Analyst View >ARDX

Ardelyx Shares Rally on 4Q Update, Bullish Analyst View >ARDX...…

Ardelyx adds 16% as Wedbush upgrades after Q4 earnings

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pre-market Movers: Bullfrog AI, Veru Inc., Ardelyx, G Medical Innovations, Arcadia Biosciences

SANTA CLARA (dpa-AFX) - The following are some of the stocks making big moves in Fridays pre-market trading (as of…

Ardelyx upgraded to outperform from neutral at Wedbush

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the…

Ardelyx Shares Rise 9.34% After Hours Following 4Q Results

Ardelyx Shares Rise 9.34% After Hours Following 4Q Results...…

Form 10-K ARDELYX, INC. For: Dec 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a…

Insiderhandel: Chief Development Officer verkauft Aktien von Ardelyx im Wert von 13.528$

Rosenbaum, David P. - Vorstand - Tag der Transaktion: 2023-02-21...…

Insiderhandel: Vorstand verkauft Aktien von Ardelyx im Wert von 9.645$

Felsch, Robert Ora - Vorstand - Tag der Transaktion: 2023-02-21...…

Insiderhandel: Chief Financial Officer verkauft Aktien von Ardelyx im Wert von 10.320$

Renz, Justin A. - Vorstand - Tag der Transaktion: 2023-02-21...…

Insiderhandel: Chief Medical Officer verkauft Aktien von Ardelyx im Wert von 9.564$

Williams, Laura A. - Vorstand - Tag der Transaktion: 2023-02-21...…

Insiderhandel: President & CEO verkauft Aktien von Ardelyx im Wert von 40.360$

Raab, Michael - Vorstand - Tag der Transaktion: 2023-02-21...…

Insiderhandel: Vorstand verkauft Aktien von Ardelyx im Wert von 10.185$

Blanks, Robert - Vorstand - Tag der Transaktion: 2023-02-21...…

Insiderhandel: Vorstand verkauft Aktien von Ardelyx im Wert von 8.745$

Grammer, Elizabeth A. - Vorstand - Tag der Transaktion: 2023-02-21...…

Ardelyx (ARDX) Gains As Market Dips: What You Should Know

Ardelyx (ARDX) closed the most recent trading day at $2.95, moving +0.34% from the previous trading session....…

Ardelyx (ARDX) Stock Sinks As Market Gains: What You Should Know

Ardelyx (ARDX) closed at $3.02 in the latest trading session, marking a -1.63% move from the prior day....…

Ardelyx (ARDX) Gains As Market Dips: What You Should Know

In the latest trading session, Ardelyx (ARDX) closed at $3.31, marking a +0.91% move from the previous day....…

Ardelyx (ARDX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Ardelyx (ARDX) closed at $3.07, marking a +1.99% move from the previous day....…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,…

Ardelyx Up 16%, Rebounding From Thursday Decline

Ardelyx Up 16%, Rebounding From Thursday Decline...…

Thinking about buying stock in Esports Entertainment, Ardelyx, Gaotu Techedu, Hoth Therapeutics, or IQIYI?

NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMBL, ARDX, GOTU, HOTH, and IQ. To…

Ardelyx Appeal of Xphozah Denial Granted by FDA

Ardelyx Appeal of Xphozah Denial Granted by FDA...…

Ardelyx rises ~10% as FDA grants appeal for kidney disease drug, refiling plans in H1 2023

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx stock rises as FDA grants appeal for new drug application for Xphozah

Ardelyx Inc. ARDX stock is up 5.2% in premarket trades on Thursday after the Waltham, Mass., biopharmaceutical company said the…

Form 8-K ARDELYX, INC. For: Dec 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Dec. 23, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,…

Thinking about buying stock in Core Scientific, DBV Technologies, Gaotu Techedu, New Oriental Education, or Ardelyx?

NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CORZ, DBVT, GOTU, EDU, and ARDX. To…

Futures Rise On China Growth Hopes

Futures Rise On China Growth Hopes After US stocks…

Ardelyx Shares Lower Premarket on Delay in FDA Xphozah Appeal >ARDX

Ardelyx Shares Lower Premarket on Delay in FDA Xphozah Appeal >ARDX...…

Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

WALTHAM, Mass., Dec. 16, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,…

Insiderhandel: Chief Development Officer verkauft Aktien von Ardelyx im Wert von 3.796$

Rosenbaum, David P. - Vorstand - Tag der Transaktion: 2022-11-22...…

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

WALTHAM, Mass., Nov. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover,…